European Society for Medical Oncology Breast Cancer Annual Congress (ESMO Breast Cancer 2026)
Berlin, Germany 06 May 2026 - 08 May 2026
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
21 May 2026
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
20 May 2026
Standard vs custom-made post-mastectomy prosthesis: Which is better?
A study presented at ESMO Breast Cancer 2026 shows that a custom-made external breast prosthesis has a slight advantage over a standard prosthesis among breast cancer patients who have undergone mastectomy.
Standard vs custom-made post-mastectomy prosthesis: Which is better?
19 May 2026
Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer
In the PREcoopERA window-of-opportunity trial, the selective estrogen receptor degrader (SERD) giredestrant shows robust anticancer activity, either alone or in combination with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin, in premenopausal women with ER+/HER2– operable invasive breast cancer.